n-t visibl way limit downgrad perform
assum coverag outperform nda
assum coverag outperform await data
review recorlev catalyst could lead share break
analyst certif import disclosur see
major headwind rear view maintain outperform
posit result guid rais pt
first look result
strong result effici guid miner acreag
clean set stage leverag creep bear
punit valuat persist despit growth
surpris result effici guidanc introduc
strong finish year outlook
n-t visibl way limit downgrad perform
lower rate ww wtw perform outperform remov price target share previous last night
ww post somewhat softer plan dec result decidedli downbeat initi outlook predic weak recruit
growth start year remain encourag longer term strateg direct ww manag abil success guid
brand digit transform time said nearer term visibl improv result decidedli limit particularli given
appear signific shortfal new subscrib recruit season meaning mar recommend wtw
specul valu play continu monitor stori close indic stabil ultim strengthen trend compani
fragil earn period ps white provid plenti fodder bear production/earn miss despit higher capital-expenditure
sharpli higher expect infrastructur spend outlook support longer term growth white continu
gener magnitud impact flattish total product conceptu understand decis self-fund
infrastructur build-out versu use third parti weigh fcf/deleverag these may attract valu investor build
sell midstream strategi appear optim us await comment angl ceo brad holli need justifi decis
self-fund infrastructur build-out amid flatten product leverag profil unlik declin meaning
assum coverag outperform nda
assum coverag outperform rate month price target impress efficaci
r/r follicular lymphoma demonstr lead candid tazemetostat enabl drug becom line treatment choic
mutat well drive use within wild-typ popul nda submiss all-com expect
content overlap next quarter initi file epithelioid sarcoma facilit review believ indic support
sale potenti us within plan commerci adequ fund oper
expect share outperform tazemetostat progress develop approach commerci
assum coverag outperform await data
assum coverag outperform rate month price target prior valu driver
oncology-focus novel inhibitor shown encourag phase efficaci r/r follicular lymphoma
look forward matur durabl data present expect eventu split fl market
inhibitor tazemetostat within patient possess activ mutat pracinostat oral hdac inhibitor
pois routin adjunct use current aml therapi chemo-intoler popul partner helsinn midway
review recorlev catalyst could lead share break
strongbridg report sales/earn provid busi updat investor highlight continu execut across
busi upcom catalyst oper result fell line manag revis guidanc
includ conserv keveyi growth estim regulatori visibl acceler approv file sonic
data phase data catalyst logic anticip recorlev year believ share pois potenti inflect given
current level updat number stay bullish
sale y/i well our/street estim led strong us pump shipment y/
higher intern perform strong pump sale support august basal-iq launch acceler momentum
pump renew well opportun us/ou creat anima exit gross margin beat vs
guidanc ahead versu our/street includ robust expect intern
also announc ceo blickenstaff transit new execut chairman role succeed john
sheridan control-iq clinic studi follow-up expect complet april ada present anticip launch
evh guidanc pressur stock near term investor process variou move part caus number uncertainti
wind-down provider-bas plan mdwise client lower expect enrol fl late start
recent contract conserv approach passport health revenu pressur core adj servic revenu revenu weak
disappoint essenti trim riskiest portion improv qualiti number go forward move toward valu base
care inevit like straight path transit remain core thesi stock valuat reset compani
goe transit period reiter outperform rate cut price target
within context undoubtedli well deservedli admir financi servic compani year investor day
rel restrain affair anyth wrongcredit remain outstand market share indic almost head
posit direct profit capit ratio ampl enough fund continu larg capit return investor addit on-going
invest busi said time last year signific tailwind corpor tax cut rise rate
rate hike on-going benefit tax tailwind lap decemb market bruhaha drive high
teen trade result
actinium atnm present four abstract transplant cellular therapi meet tct feb houston tx late break
oral present receiv high profil meet analog atnm high-profil present detail
previous atnm also present preclin data demonstr single-infus transient lymphodeplet potenti use cell therapi
procedur like car-t data materi thesi build upon manag continu execut
busi strategi develop innov target payload immunotherapeut treatment advanc cancer stay bullish
tuesday compugen report result review recent progress call learn on-going phase trial
advanc initi acceler dose escal standard cohort expect dose escal opdivo
combin commenc clinic collabor bristol-my squibb bm dose escal monotherapi combin
trial could complet later year conserv cash compugen focus resourc tigit-target reduc
oper expens workforc reduct restructur could potenti extend compugen cash runway
would buyer stock ahead potenti clinic proof-of-concept could deliv next month reiter
gwph report result beat estim primarili driven higher epidiolex revenu lower oper expens
manag provid revenu guidanc indic broader coverag expand distribut network bolu patient
unfil script expect drive epidiolex uptak also note expect oper expens meaning
higher vs driven eu launch prepar expens increas revenu estim howev
maintain pt higher share count vs prior estim gwph appear well posit revenu growth believ
fairli reflect stock current level maintain perform rate
report result higher estim top bottom line primarili driven solid product uptak across
major portfolio manag guidanc suggest continu revenu growth franchis well earn growth despit
higher oper expens primarili driven increas sg invest pre-launch launch activ continu view ed
franchis stabl platform look forward data solriamfetol regulatori action year hematolog franchis
view continu area invest look vyxeo uptak eu potenti erwinaz volatil continu suppli
constraint maintain outperform rate price target
consist check deliv strong result beat consensu estim across board rais guidanc
revenue/ep beat consensu guidanc stellar perform driven healthi secur spend
robust product growth revenu y/i exceed street emea revenu grew y/i repres
fastest grow region illustr significantli gain presenc region addit demisto acquisit orchestr
autom introduc cortex xdr- ai/ml secur platform integr network endpoint cloud data top demisto
autom capabl view product strategi favor align long-term vision becom lead security-
as-an-infrastructur saai provid rais pt
major headwind rear view maintain outperform
consist preview rais guidanc valuepenguin acquisit insur maintain initi
outlook investor day comfort beat-and-rais potenti compar improv mortag backdrop
insur scale market platform mortgag potenti re-acceler top line growth repres
next catalyst monitor deceler credit card revenu y/i vs guidanc assum comparecard brand mlt
integr acceler segment revenu expect investor push-back acquisit gener larg portion growth
believ view underappreci platform abil scale single-vert player risk near-term bullish view greater deceler
person loan maintain outperform pt
emerg technolog servic
look past vievu integr cost well new product transit lot like axon result first compani continu
set record book second manag outlin low hang fruit way public servic provid compani
core product bodi camera/evid manag third doubl sensor/servic model addit product drone cad
rm hand unnam project axon bodi rm taser roll cours slower growth
worri investor remain sidelin believ investor disappoint lack leverag
wp deliv strong result organic/cc revenu growth ep vs our/street estim provid
encourag guidanc direct consist prior expect notabl post strong organic/cc
revenu growth acceler e-commerce integr payment perform well merchant issuer grew
organic/cc line expect wp guidanc anticip revenu growth ep vs prior wp
anticip cumul cost synergi maintain target run-rat revenu synergi goal exit
share trade revis ep believ wp remain attract maintain outperform rate pt
report solid result opinion consid mortgag headwind manag suggest unit headwind
quarter y/i revenu declin vs estim also adj ebitda beat estim reflect
margin upsid outlin guidanc includ anticip wind-down transform certain busi
anticip revenu reflect drag wind-down transform adj ebitda consid
discret headwind adj ep prior estim adjust aforement discret item would
approxim high end rang await manag commentari around core growth initi market-rel drag anticip
headwind transform softwar wind-down estim review
help growth voi sale report adjust ebitda compar our/street estim
tour saw yoy increas improv provis loan loss remain flat yoy guidanc
call revenu yoy vs our/street adjust ebitda yoy
vs our/street first-quart could see modest revenu growth tour growth yoy soft
new sale center ramp lower exchang revenu per member adjust ebitda
sustain growth resourc optim
posit result guid rais pt
beat expect guid consensu gm mid-point q/q inclus mileston
payment believ mix toward reach well dedic igbt suppli lower air ship cost help
drive margin higher commentari point addit cost save throughout compon avail improv manag also
note oper target start look like om om adjust estim account longer
compon shortag follow share gain enabl increas capac shorter lead time cost reduct pt move
introduc ep appli multipl
sustain growth resourc optim
first look result
beat adj sales/ebitda consensu strong perform portfolio product sale guid adj ebitda
midpoint street estim outlook electr segment sale growth y/i ex puna benefit recent portfolio addit
 mcgin hill full year usg plant prior estim assum puna contribut guidanc midpoint
review portfolio mix assumpt model product outperform expect quarter enter
lower backlog prior year believ greater divers well total growth key strateg focu expect
updat energi storag growth strategi follow impair earn-out revers virid manag note
segment new leadership earn call et today
strong result effici guid miner acreag detail announc
expect modest posit reaction strong oper result off-set concern leverag creep matador provid high-qual
earn beat oil volum strong cash opex perform compani introduc effici outlook oil product
forecast us capital-expenditure us note detail releas introduct royalti acreag detail
net acr focus activ rustler break area total royalti acr temper enthusiasm anoth uptick leverag
support view matador activ asset sale front
clean set stage leverag creep bear monitor
expect modest posit reaction oili earn beat lower expect result earlier callon report
earn exceed expect note strong cash unit expens bullish oper updat show
product flank permian basin leverag approach focu turn capital-expenditure disciplin non-cor asset sale
deliv strong well never concern callon capit intens execut issu infrastructur
place duc inventori establish look forward hear current develop thought wednesday call
punit valuat persist despit growth visibl reiter outperform
modest under-perform seen date tuesday trail xop understand given noisi result magnolia first
full quarter outlook crystal follow detail guidanc given call remain bullish share robust non-
oper activ karn counti continu growth expect gid show oper momentum place product
guidanc conserv opaqu view still see steadi earn growth world
expect persist
remain perform-r crzo share follow earn updat commentari pad/cube-styl develop across core asset
appear consist goal drive effici busi success cube-styl develop across three wolfcamp
horizon could drive upward reset inventory/growth area pivot away eagl ford shale give us paus feed
inventori concern play see upsid potenti state delawar basin inventori increasingli gassi skew asset
weigh drill econom model show leverag y/e gener medium-
term acquisit grow resourc base possibl may weigh crzo share valuat
surpris result effici guidanc introduc
expect share react favor effici growth outlook provid result mostli line us although
consensu compani announc significantli slimmed-down oper plan capital-expenditure
product still expect grow y/i hope learn conserv capital-expenditure figur follow disappoint capital-expenditure figur
one tailwind capital-expenditure decis let oasi midstream partner carri oasi growth capital-expenditure bobcat gather subsidiari
own entiti carri serv modest sell-down
strong finish year outlook
adjust ep y/i exceed estimate/consensu total revenue/rent revenu
y/i compar estim mobil modular rental revenu remain strong
y/i trs-rentelco adler tank rental revenu grew y/i sixth/eighth consecut quarter y/i growth adjust
ebitda y/i top estim scale solid revenu growth across cost structur strong finish
good continu healthi busi condit prompt oper incom growth guidanc y/i increas
prior estim appear posit deliv solid result
june summit emerg biotechnolog montauk ny
